CIBMTR® Clinical Outcomes Registry
Automates Data Collection
to Accelerate Life-Saving Research

Minneapolis, MN, and Durham, NC, October 22, 2020 — The CIBMTR® (Center for International Blood and Marrow Transplant Research®), a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin, is pioneering the automation of transmitting electronic medical record data from its research network partners to its outcomes registry.

Driving innovation for patients
We don’t have an exact roadmap to follow—this has never been done before—but we know what we’re doing is necessary to save lives and help patients thrive after transplant. Bringing data together in a timely manner accelerates research to reveal new insights and transcend scientific frontiers. By treating entrusted data as an asset for the public good and investing in realizing its full value, the CIBMTR will promote breakthroughs to make a more successful patient journey.

Pilot testing a prototype
CIBMTR has relied on a web-based model of data collection using an extensive library of forms that come due at intervals across a transplant patient’s lifespan. Under a new model, we have successfully brought together healthcare data standards that enable our research network partners to collect and send data from their source data systems efficiently and securely. This new model using our prototyped set of solutions, is both future-proof and sustainable because it meets the data where it resides and allows data to become interoperable.

We moved quickly to design and test our prototype within a pilot. In six months, we partnered with five diverse transplant centers for the pilot. The results are in and it worked!

“In my 35+ years of tenure as Chief Scientific Director of the CIBMTR, this initiative is one of the most important things we’ve done to position the CIBMTR to meet the research needs of our community.”
Mary Horowitz, MD, MS, Chief Scientific Director, CIBMTR

Not only does the new model help accelerate research through timely data reporting, pilot centers reported that reducing data entry requirements should provide cost-savings through efficiencies gained under the new model. This perceived value has the potential to allow scarce healthcare resources to become directed back into patient care.
“The success achieved in this initiative to date brings the promise of translational science to patients and supports transplant centers under financial strain in reducing their administrative cost and resource burden to submit critical data for clinical research,” Steven Devine, MD, Associate Scientific Director, CIBMTR and Chief Medical Officer, NMDP/Be The Match.

A team effort
We want to thank our transplant center partners who participated in the pilot:

- Children’s Hospital of Colorado
- Moffitt Cancer Center
- Oregon Health & Science University / Knight Cancer Institute
- Sarah Cannon Research Institute
- The Ohio State University

We are truly thankful for their determination and problem-solving skills—we could not have done this without them. Through collaboration, our learnings have helped pave the future for a new era of clinical registry reporting and our ability to scale this to the CIBMTR network more quickly and efficiently.

Our vendor partner, IQVIA, brought their expertise and extensive resources to help design and create a customized solution aligned with the vision of the initiative to optimize data acquisition for the CIBMTR. This solution allows centers to be in control of every aspect of the process with incremental value to the centers as new functionality becomes enabled.
About the CIBMTR
The CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database.

For more information on the CIBMTR, please visit www.cibmtr.org or follow the CIBMTR on Facebook, LinkedIn, or Twitter at @CIBMTR.

About the National Marrow Donor Program (NMDP)/Be The Match
The National Marrow Donor Program® (NMDP)/Be The Match® is the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia and lymphoma, as well as other diseases. The NMDP/Be The Match manages the world’s largest registry of potential blood stem cell donors and cord blood units, connects patients to their donor match for a life-saving marrow or umbilical cord blood transplant and educates health care professionals and patients. In 2016, the NMDP/Be The Match established Be The Match BioTherapies® to accelerate patient access to life-saving therapies, by providing proven services and support to companies developing and delivering cell and gene therapies.

Learn more at BeTheMatchClinical.org.

About the Medical College of Wisconsin
With a history dating back to 1893, The Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,400 students are enrolled in MCW’s medical school and graduate school programs in Milwaukee, Green Bay, and Central Wisconsin. MCW’s School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In the last ten years, faculty received more than $1.5 billion in external support for research, teaching, training and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,600 physicians provide care in virtually every specialty of medicine for more than 2.8 million patients annually.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 68,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy
while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.